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ABSTRACT: Monoacylglycerol lipase (MGLL or MAGL) is a critical point of regulation of both endocannabinoid and
eicosanoid signaling pathways in the brain, thereby providing novel therapeutic opportunities for neurological and
neurodegenerative diseases. In this issue Cisar et al. disclose the discovery, optimization, and initial preclinical proﬁling of ABX-
1431, a covalent, irreversible MGLL inhibitor. Activity-based protein proﬁling was key to the discovery of ABX-1431. ABX-1431
is a ﬁrst-in-class experimental drug that was well-tolerated and safe in phase 1 clinical studies. Data from an exploratory phase 1b
study indicate that it has the potential to treat symptoms of adult patients with syndrome of Gilles de la Tourette. ABX-1431 is
currently entering clinical phase 2 studies for this neurological disorder as well as for other indications, such as neuromyeltis
optica and multiple sclerosis.
Drug discovery for disorders of the central nervous system(CNS) is hard. Several factors contribute to the daunting
task to discover novel therapies for brain diseases. First and
foremost, there is a lack of validated therapeutic targets largely
because of our limited understanding of the function of the
brain in health and disease. Once a potential suitable target has
been identiﬁed, the optimization of small molecules into drug
candidates is complicated by the strict physicochemical
properties required to pass the blood−brain barrier.
Furthermore, the determination of the target-interaction
landscape (i.e., its selectivity proﬁle) of the drug in human
brain is essential to avoid disasters as recently witnessed with
fatal phase 1 clinical trial of BIA 10-2474. A volunteer died due
to an overdosis of BIA 10-2474.1 Thus, studies enabling target
and oﬀ-target engagement in the brain are essential to guide
drug discovery and development.2,3 In this issue of J. Med.
Chem. Cisar and colleagues report the discovery, optimization,
and proﬁling of ABX-1431 (Figure 1), a ﬁrst-in-class
experimental drug of monoacylglycerol lipase (MGLL, also
termed as MAG lipase), using activity-based protein proﬁling
for the treatment of neurological disorders, including neuro-
pathic pain and syndrome of Gilles de la Tourette.4
MGLL is a membrane-bound enzyme that belongs to the
family of serine hydrolases.5,6 It is the principal metabolic
enzyme that controls the levels of 2-arachidonoylglycerol (2-
AG) in the brain.7 2-AG acts as an endogenous agonist of the
cannabinoid CB1 and CB2 receptors. MGLL catalyzes the
hydrolysis of the ester bond in 2-AG, thereby terminating the
2-AG-mediated signaling of the CB1/CB2 receptor and
producing arachidonic acid and glycerol (Figure 1). 2-AG
serves as an important source of arachidonic acid, the
precursor of proinﬂammatory prostaglandins, in the brain. In
vivo studies have shown that inhibition of MGLL leads to CB
receptor dependent antinociceptive eﬀects in mouse models of
inﬂammatory and neuropathic pain. MGLL inhibitors exert
also anxiolytic and anti-inﬂammatory eﬀects. In various animal
models of neurodegeneration, including Parkinson’s disease,
Alzheimer’s disease, and acute brain injury, MGLL inhibition
exerted neuroprotective eﬀects by reducing proinﬂammatory
prostanoid and cytokine signaling independent of the CB1
receptor. Thus, emerging data suggest that MGLL is a critical
point of regulation of both endocannabinoid and eicosanoid
signaling pathways in the brain, thereby providing novel
therapeutic opportunities.
To this end, several academic groups and pharmaceutical
companies have developed MGLL inhibitors that have a
reversible or irreversible mode-of-action.8 Irreversible inhib-
itors that covalently interact with the catalytic serine (Ser-122)
of MGLL, may achieve higher potency and sustained
inactivation of the enzyme, thereby putting less demand on
the pharmacokinetic properties. Determination of the
selectivity proﬁle of mechanism-based covalent inhibitors is,
however, essential because other proteins from the same
enzyme family of the primary target may also react with the
warhead of the experimental drug in the same fashion. This
could lead to unwanted side eﬀects or toxicity. BIA 10-2474,
for instance, is a mechanism-based covalent fatty acid amide
hydrolase inhibitor that reacted with several lipases and
disrupted the metabolic proﬁle of human cortical neurons.3
Thus, assessment of the interaction proﬁle of the covalent
inhibitor in human cells and brain is important.
Cisar et al. used activitity-based protein proﬁling (ABPP) as
the central technology for the discovery, optimization, and
proﬁling of their clinical MGLL inhibitor ABX-1431.4
Competitive ABPP is an eﬃcient chemical biology approach
to study target engagement and interaction-landscape of
covalent irreversible inhibitors in living systems.2,3 It makes
use of broad-spectrum chemical probes that report on the
abundance of active enzymes in lysates, (human) cells, or even
intact animals. The interaction of a small molecule with
endogenously expressed enzymes, including all post-transla-
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tional modiﬁcations, protein−protein interactions in the
presence of endogenous substrates, can be assessed in one
single experiment. ABPP makes use of activity-based probes
consisting of warhead, recognition element, and reporter
group. A ﬂuorescent reporter group is used for gel-based
ABPP, whereas a biotin reporter allows mass spectrometry
(MS)-based identiﬁcation of the interacting proteins.
Cisar et al. used the prototypical ﬂuorophosphonate (FP)-
based probes to assess the interaction of their MGLL inhibitors
on the serine hydrolase family.4 JZL184 and KML29 were used
as a starting point for the rational design of novel MGLL
inhibitors. Careful optimization of the activity and selectivity
using gel-based ABPP with multiple human proteomes and
rodent brain homogenates led to the discovery of ABX-1431
(1,1,1,3,3,3-hexaﬂuoropropan-2-yl-4-(2-(pyrrolidin-1-yl)-4-
(triﬂuoromethyl)benzyl)piperazine-1-carboxylate), which was
selected as the lead compound for clinical evaluation. ABX-
1431 is a potent human MGLL inhibitor with an average IC50
of 14 nM that only cross-reacted to a minor extent with α,β-
hydrolase domain containing protein 6 (ABHD6), PLA2G7,
and some carboxylesterases. The compound maintained
activity and selectivity in human cellular assays and in
human prefrontal cortex proteomes as determined by MS-
based ABPP. ABX-1431 is a lipophilic molecule and has a basic
amine, yet it has only weak hERG channel activity with an IC20
of 7 μM. The compound did not display any signiﬁcant activity
against a panel of common oﬀ-targets and has low propensity
to CYP-inhibition. ABX-1431 demonstrated acceptable
pharmacokinetics in rodents and dogs. It inhibited MGLL
activity with an ED50 of 0.5−1.4 mg/kg (po) and dose-
dependently increased brain 2-AG levels in mouse brain. A rat
inﬂammatory pain model was used to assess the pharmacody-
namics eﬀect. ABX-1431 demonstrated potent antinociceptive
eﬀects in a formalin paw test at a dose that produced near
complete MGLL inhibition and maximal elevation of 2-AG.
Other pharmacological eﬀects were not (yet) described.
Currently, ABX-1431 is being tested in at least ﬁve diﬀerent
clinical trials (www.clinicaltrials.gov). Notably, it has success-
fully completed phase 1 clinical trials.10 The compound was
generally well-tolerated and safe. The most commonly
observed adverse eﬀects were headache, somnolence, and
fatigue. It inhibited MGLL in the brain in a dose-dependent
manner as demonstrated with a PET study. Importantly, in a
randomized, double-blind, placebo-controlled crossover, ex-
ploratory phase 1b study, ABX-1431 was able to show a
positive impact on key measures of symptoms in adult patients
with the syndrome of Gilles de la Tourette.10 It is now entering
phase 2 clinical trial for this indication (NCT03625453). The
compound will also be tested in neuromyeltis optica, multiple
sclerosis and as an add-on therapy in patients suﬀering from
central neuropathic pain (NCT03138421).
In summary, ABX-1431 is a ﬁrst-in-class MGLL inhibitor
that was discovered and optimized using ABPP. ABX-1431 has
entered phase 2 clinical trials and shows promising preliminary
results in patients suﬀering from a neurological disease. It will
be interesting to see whether MGLL inhibitors mimic some of
the psychoactive eﬀects of cannabinoid CB1 receptor agonists,
such as Δ9-THC, the psychoactive component in marijuana, or
whether chronic dosing leads to functional antagonism of the
CB1 receptor.
5,9 Finally, the study presented by Cisar et al.
emphasizes the crucial role of ABPP in drug discovery and
development of covalent irreversible inhibitors and will spur
the ﬁeld of MGLL inhibitors. It is hoped that MGLL
inhibitors, such as ABX-1431, may provide a new treatment
option for Tourette’s syndrome and patients with neuro-
inﬂammatory conditions.
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■ ABBREVIATIONS USED
MGLL or MAGL, monoacylglycerol lipase; 2-AG, 2-arach-
idonoylglycerol; CB1R, type 1 cannabinoid receptor; CB2R,
Figure 1. Clinical candidate ABX-1431 is a monoacylglycerol lipase (MGLL) inhibitor that prevents the hydrolysis of the endocannabinoid 2-
arachidonoylglycerol in the human brain. It prolongs the action of 2-arachidonoylglycerol on the cannabinoid CB1 and CB2 receptors and reduces
the formation of arachidonic acid, the substrate of proinﬂammatory prostanoids, thereby alleviating neurological symptoms and reducing
neuroinﬂammation.
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type 2 cannabinoid receptor; ABPP, activity-based protein
proﬁling; FP, ﬂuorophosphonate; ABHD6, α,β-hydrolase
domain containing protein 6
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